Chemotherapy-Associated Thrombosis

  • Aneel A. Ashrani
  • S. Vincent Rajkumar
Part of the Cancer Treatment and Research book series (CTAR, volume 148)

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a multifactorial disease, involving complex interactions between individuals (including their hemostatic system and genetic predispositions) and their environmental exposures. Active malignancy is a well recognized risk factor for VTE and accounts for almost 20% of incident VTE events occurring in the community [1], with chemotherapy independently adding to that risk [2, 3]. As compared with the general population, the risk of VTE is increased fourfold in patients with cancer and this risk is further elevated to more than sixfold when these patients are receiving chemotherapy [2]. Moreover, there is a twofold increase in recurrent VTE in patients with malignancy and a fourfold increase in this risk for those receiving chemotherapy [2]. In addition, the risk of VTE varies by cancer type and stage [3–6]. The type of chemotherapy administered, hormonal treatments, immunomodulating and anti-angiogenesis agents (e.g., thalidomide, lenalidomide, bevacizumab), and supportive therapy with hematopoietic growth factors like recombinant human erythropoietins have been implicated in alterations in hemostasis and with increased VTE risk.


Multiple Myeloma Polycythemia Vera Essential Thrombocythemia Recombinant Human Erythropoietin Gemtuzumab Ozogamicin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002 Jun 10;162(11):1245–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000 Mar 27;160(6):809–15.Google Scholar
  3. 3.
    Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006 Mar;4(3):529–35.PubMedCrossRefGoogle Scholar
  4. 4.
    Heit JA, Petterson TM, Marks RS, Bailey KR, Melton LJ III. The risk of venous thromboembolism (VTE) among cancer patients by tumor site: a population-based study. Blood (ASH Annual Meeting Abstracts). 2004 November 16, 2004;104(11):2596.Google Scholar
  5. 5.
    Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. Jama. 2005 Feb 9;293(6):715–22.PubMedCrossRefGoogle Scholar
  6. 6.
    Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006 Feb 27;166(4):458–64.PubMedCrossRefGoogle Scholar
  7. 7.
    Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999 Sep;78(5):285–91.CrossRefGoogle Scholar
  8. 8.
    Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000 Sep;18(17):3078–83.PubMedGoogle Scholar
  9. 9.
    Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002 Nov 15;100(10):3484–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000 Dec 21;343(25):1846–50.PubMedCrossRefGoogle Scholar
  11. 11.
    Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med. 1975;6(1):61–4.PubMedGoogle Scholar
  12. 12.
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007 Mar;5(3):632–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006; 118(5):555–68.PubMedCrossRefGoogle Scholar
  14. 14.
    Cool RM, Herrington JD, Wong L. Recurrent peripheral arterial thrombosis induced by cisplatin and etoposide. Pharmacotherapy. 2002 Sep;22(9):1200–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Cwikiel M, Eskilsson J, Albertsson M, Stavenow L. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol. 1996 Sep;7(7):731–7.PubMedGoogle Scholar
  16. 16.
    Cwikiel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M. The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc. 1996;10(3):805–18; discussion 19.PubMedGoogle Scholar
  17. 17.
    Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation. Scanning. 2001 Jan-Feb;23(1):1–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology. 1985;42(5):296–300.PubMedCrossRefGoogle Scholar
  19. 19.
    Oner AF, Gurgey A, Kirazli S, Okur H, Tunc B. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase. Leukemia Lymphoma. 1999 Apr;33(3–4):361–4.PubMedGoogle Scholar
  20. 20.
    Grem JL, McAtee N, Murphy RF, Hamilton JM, Balis F, Steinberg S, et al. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. J Clin Oncol. 1994 Mar;12(3):560–8.PubMedGoogle Scholar
  21. 21.
    Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med. 1996 Sep 9;156(16):1806–10.PubMedCrossRefGoogle Scholar
  22. 22.
    Ramsay NK, Coccia PF, Krivit W, Nesbit ME, Edson JR. The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia. Cancer. 1977 Oct; 40(4):1398–401.PubMedCrossRefGoogle Scholar
  23. 23.
    Rogers JS II, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol. 1988 Feb;6(2):276–81.PubMedGoogle Scholar
  24. 24.
    Bertomeu MC, Gallo S, Lauri D, Levine MN, Orr FW, Buchanan MR. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastas. 1990 Nov–Dec;8(6): 511–8.CrossRefGoogle Scholar
  25. 25.
    Greeno EW, Bach RR, Moldow CF. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest; J Tech Method Pathol. 1996 Aug;75(2): 281–9.Google Scholar
  26. 26.
    Mills PJ, Parker B, Jones V, Adler KA, Perez CJ, Johnson S, et al. The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. Clin Cancer Res. 2004 Aug 1;10(15):4998–5003.PubMedCrossRefGoogle Scholar
  27. 27.
    Wang J, Weiss I, Svoboda K, Kwaan HC. Thrombogenic role of cells undergoing apoptosis. Br J Haematol. 2001 Nov;115(2):382–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Throm Res. 2000 Sep 1;99(5):503–9.CrossRefGoogle Scholar
  29. 29.
    Walsh J, Wheeler HR, Geczy CL. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol. 1992 Aug;81(4):480–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Caine GJ, Stonelake PS, Rea D, Lip GY. Coagulopathic complications in breast cancer. Cancer. 2003 Oct 15;98(8):1578–86.PubMedCrossRefGoogle Scholar
  31. 31.
    Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989 Feb 23;320(8):479–84.PubMedCrossRefGoogle Scholar
  32. 32.
    Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol. 1994 Jun;12(6):1266–71.PubMedGoogle Scholar
  33. 33.
    Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Seminars in thrombosis and hemostasis. 1999;25(2):137–45.PubMedCrossRefGoogle Scholar
  34. 34.
    Pemberton KD, Melissari E, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis. 1993 Dec;4(6): 935–42.PubMedGoogle Scholar
  35. 35.
    Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, Roberts JD, et al. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br J Haematol. 2003 Jan;120(1):109–16.PubMedCrossRefGoogle Scholar
  36. 36.
    Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997 Nov 19;89(22):1673–82.PubMedCrossRefGoogle Scholar
  37. 37.
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16;90(18):1371–88.PubMedCrossRefGoogle Scholar
  38. 38.
    Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol. 2003 Oct 1;21(19):3588–93.PubMedCrossRefGoogle Scholar
  39. 39.
    McCaskill-Stevens W, Wilson J, Bryant J, Mamounas E, Garvey L, James J, et al. Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen. J Natl Cancer Inst. 2004 Dec 1;96(23):1762–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004 Aug 1;101(3):439–49.PubMedCrossRefGoogle Scholar
  41. 41.
    Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002 Jun 22;359(9324):2131–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998 Mar 23;158(6):585–93.PubMedCrossRefGoogle Scholar
  43. 43.
    Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002 Apr;87(4):575–9.PubMedGoogle Scholar
  44. 44.
    Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004 Aug 1;101(3):558–66.PubMedCrossRefGoogle Scholar
  45. 45.
    Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006 Jan 20;24(3):431–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006 Mar 11;367(9513):825–31.PubMedCrossRefGoogle Scholar
  47. 47.
    Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007 Oct 6;370(9594):1209–18.PubMedCrossRefGoogle Scholar
  48. 48.
    Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med. 2004 Oct 1;117(7):508–15.PubMedCrossRefGoogle Scholar
  49. 49.
    Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996 Mar;31(2–3):213–21.PubMedCrossRefGoogle Scholar
  50. 50.
    Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003 Apr;17(4): 775–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003 Jan 1;21(1):16–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Rajkumar SV, Rosinol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008 May 1;26(13):2171–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001 Jul 15;98(2):492–4.PubMedCrossRefGoogle Scholar
  54. 54.
    Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res. 2002 Nov;8(11):3377–82.PubMedGoogle Scholar
  55. 55.
    Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW. A UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leukemia Res. 2003 Oct;27(10):909–14.CrossRefGoogle Scholar
  56. 56.
    Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002 Nov 1;20(21):4319–23.PubMedCrossRefGoogle Scholar
  57. 57.
    Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004 Jul;89(7):826–31.PubMedGoogle Scholar
  58. 58.
    Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol. 2003 Jun;121(5):768–71.PubMedCrossRefGoogle Scholar
  59. 59.
    Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J. 2004;5(4):318–24.PubMedCrossRefGoogle Scholar
  60. 60.
    Dimopoulos MA, Anagnostopoulos A, Terpos E, Repoussis P, Zomas A, Katodritou E, et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica. 2006 Feb;91(2): 252–4.PubMedGoogle Scholar
  61. 61.
    Offidani M, Corvatta L, Marconi M, Olivieri A, Catarini M, Mele A, et al. Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J. 2004;5(4):312–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001 Jun 21;344(25):1951–2.PubMedCrossRefGoogle Scholar
  63. 63.
    Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli C, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol. 2004 Jan;15(1):134–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Schutt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoiczyk M, et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol. 2005 Jan;74(1):40–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin proc. 2005 Dec;80(12): 1568–74.Google Scholar
  66. 66.
    Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma. 2003 Jun;4(1):32–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Kumar S, Zhang L, Greipp PR, Rajkumar SV. Effect of thrombotic events on overall survival in patients with newly diagnosed myeloma: analysis from a randomized phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00). Blood. 2007;110(11):Abstract #2734.Google Scholar
  68. 68.
    Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002 Oct 15;95(8):1629–36.PubMedCrossRefGoogle Scholar
  69. 69.
    Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther. 2008 Jun;33(3):219–26.PubMedCrossRefGoogle Scholar
  70. 70.
    Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002 Nov 1;100(9):3063–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004 Mar 8;90(5):955–61.PubMedCrossRefGoogle Scholar
  72. 72.
    List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549–57.PubMedCrossRefGoogle Scholar
  73. 73.
    Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123–32.PubMedCrossRefGoogle Scholar
  74. 74.
    Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133–42.PubMedCrossRefGoogle Scholar
  75. 75.
    Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005 Dec 15;106(13):4050–3.PubMedCrossRefGoogle Scholar
  76. 76.
    Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. ASH Annual Meeting Abstracts. 2007 November 16, 2007;110(11):74.Google Scholar
  77. 77.
    Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006 May 11;354(19):2079–80.PubMedCrossRefGoogle Scholar
  78. 78.
    Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urology. 1998 Dec;160(6 Pt 1):2021–4.Google Scholar
  79. 79.
    Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000 May;18(10):2169–78.PubMedGoogle Scholar
  80. 80.
    Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, Di Costanzo G, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005 Mar 1;103(5):994–9.PubMedCrossRefGoogle Scholar
  81. 81.
    von Tempelhoff GF, Niemann F, Schneider DM, Kirkpatrick CJ, Hommel G, Heilmann L. Blood rheology during chemotherapy in patients with ovarian cancer. Thromb Res. 1998 Apr 15;90(2):73–82.CrossRefGoogle Scholar
  82. 82.
    Jacobson GM, Kamath RS, Smith BJ, Goodheart MJ. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol. 2005 Feb;96(2):470–4.PubMedCrossRefGoogle Scholar
  83. 83.
    Bezeaud A, Drouet L, Leverger G, Griffin JH, Guillin MC. Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. J Pediatr. 1986 May;108(5 Pt 1):698–701.PubMedGoogle Scholar
  84. 84.
    Kwaan HC. Double hazard of thrombophilia and bleeding in leukemia. Hematology Am Soc Hematol Educ Program. 2007;2007:151–7.Google Scholar
  85. 85.
    Buchanan GR, Holtkamp CA. Reduced antithrombin III levels during L-asparaginase therapy. Med Pediatr Oncol. 1980;8(1):7–14.PubMedCrossRefGoogle Scholar
  86. 86.
    Conard J, Horellou MH, Van Dreden P, Potevin F, Zittoun R, Samama M. Decrease in protein C in L-asparaginase-treated patients. Br J Haematol. 1985 Apr;59(4):725–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Priest JR, Ramsay NK, Latchaw RE, Lockman LA, Hasegawa DK, Coates TD, et al. Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer. 1980 Oct 1;46(7):1548–54.PubMedCrossRefGoogle Scholar
  88. 88.
    Gugliotta L, Mazzucconi MG, Leone G, Mattioli-Belmonte M, Defazio D, Annino L, et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Eur J Haematol. 1992 Aug;49(2):63–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost. 1995;21(4):390–401.PubMedCrossRefGoogle Scholar
  90. 90.
    Priest JR, Ramsay NK, Steinherz PG, Tubergen DG, Cairo MS, Sitarz AL, et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 1982 Jun;100(6):984–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Alberts SR, Bretscher M, Wiltsie JC, O'Neill BP, Mokri B, Witzig TE. Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement. Leukemia Lymphoma. 1999 Feb;32(5–6):489–96.PubMedGoogle Scholar
  92. 92.
    Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer. 1989 Apr 1;63(7):1303–7.PubMedCrossRefGoogle Scholar
  93. 93.
    Edwards RL, Klaus M, Matthews E, McCullen C, Bona RD, Rickles FR. Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med. 1990 Jul;89(1):25–8.PubMedCrossRefGoogle Scholar
  94. 94.
    Otten HM, Mathijssen J, ten Cate H, Soesan M, Inghels M, Richel DJ, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 2004 Jan 26;164(2):190–4.PubMedCrossRefGoogle Scholar
  95. 95.
    Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007 Jun 18;96(12):1788–95.PubMedCrossRefGoogle Scholar
  96. 96.
    Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev. 2007 Jun;7(6):475–85.CrossRefGoogle Scholar
  97. 97.
    Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol. 2003 Sep 15;21(18):3542; author reply 3.PubMedCrossRefGoogle Scholar
  98. 98.
    Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol. 2001 Jun;280(6):C1375–86.Google Scholar
  99. 99.
    Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003 Jan 1;21(1):60–5.PubMedCrossRefGoogle Scholar
  100. 100.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335–42.PubMedCrossRefGoogle Scholar
  101. 101.
    Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006 Nov 20;24(33):5201–6.PubMedCrossRefGoogle Scholar
  102. 102.
    Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27;357(26):2666–76.PubMedCrossRefGoogle Scholar
  103. 103.
    Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, et al. Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol. 2008 Jul 5.Google Scholar
  104. 104.
    Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006 May 17;98(10):708–14.PubMedCrossRefGoogle Scholar
  105. 105.
    Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. Jama. 2008 Feb 27;299(8):914–24.PubMedCrossRefGoogle Scholar
  106. 106.
    Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085–98.PubMedCrossRefGoogle Scholar
  107. 107.
    Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998 Aug 27;339(9):584–90.PubMedCrossRefGoogle Scholar
  108. 108.
    Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003 Sep 1;59(3):538–48.PubMedCrossRefGoogle Scholar
  109. 109.
    Fuste B, Serradell M, Escolar G, Cases A, Mazzara R, Castillo R, et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost. 2002 Oct;88(4):678–85.PubMedGoogle Scholar
  110. 110.
    Tobu M, Iqbal O, Fareed D, Chatha M, Hoppensteadt D, Bansal V, et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost. 2004 Jul;10(3):225–32.PubMedCrossRefGoogle Scholar
  111. 111.
    Falanga A, Marchetti M, Evangelista V, Manarini S, Oldani E, Giovanelli S, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood. 1999 Apr 15;93(8):2506–14.PubMedGoogle Scholar
  112. 112.
    Stasko J, Drouet L, Soria C, Mazoyer E, Caen J, Kubisz P. Erythropoietin and granulocyte colony-stimulating factor increase plasminogen activator inhibitor-1 release in HUVEC culture. Thromb Res. 2002 Jan 15;105(2):161–4.PubMedCrossRefGoogle Scholar
  113. 113.
    Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005 Dec 15;104(12):2822–9.PubMedCrossRefGoogle Scholar
  114. 114.
    Brotman DJ, Girod JP, Posch A, Jani JT, Patel JV, Gupta M, et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res. 2006;118(2):247–52.PubMedCrossRefGoogle Scholar
  115. 115.
    Sartori TM, Maurizio PG, Sara P, Ugolino L, Annalisa A, Panagiotis T, et al. Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. J Heart Lung Transplant. 1999 Jul;18(7):693–700.PubMedCrossRefGoogle Scholar
  116. 116.
    Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005 Oct 1;104(7):1442–52.PubMedCrossRefGoogle Scholar
  117. 117.
    Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 1997 Aug;84(8): 1099–103.CrossRefGoogle Scholar
  118. 118.
    Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999 Sep 9;341(11):793–800.PubMedCrossRefGoogle Scholar
  119. 119.
    Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002 Mar 28;346(13):975–80.PubMedCrossRefGoogle Scholar
  120. 120.
    Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 2005 Oct;92(10): 1212–20.PubMedCrossRefGoogle Scholar
  121. 121.
    Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994 Apr 9;343(8902):886–9.PubMedCrossRefGoogle Scholar
  122. 122.
    Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004 May 15;22(10):1944–8.PubMedCrossRefGoogle Scholar
  123. 123.
    Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004 Aug;2(8):1266–71.PubMedCrossRefGoogle Scholar
  124. 124.
    Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005 Apr 1;23(10):2130–5.PubMedCrossRefGoogle Scholar
  125. 125.
    Haas SK, Kakkar AK, Kemkes-Matthes B, Freund M, Gatzemeier U, Heilmann L, et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer – results of the TOPIC Studies. J Thromb Haemost. 2005;3(Supplement 1):Abstract: OR059.Google Scholar
  126. 126.
    Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl): 381S–453S.PubMedCrossRefGoogle Scholar
  127. 127.
    Minnema MC, Breitkreutz I, Auwerda JJ, van der Holt B, Cremer FW, van Marion AM, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia. 2004 Dec;18(12):2044–6.PubMedCrossRefGoogle Scholar
  128. 128.
    Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004 Sep;126(5):715–21.PubMedCrossRefGoogle Scholar
  129. 129.
    Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 9;354(10):1021–30.PubMedCrossRefGoogle Scholar
  130. 130.
    Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA–Italian Multiple Myeloma Network. J Clin Oncol. 2007 Oct 1;25(28):4459–65.PubMedCrossRefGoogle Scholar
  131. 131.
    Baz R, Walker E, Karam MA, Choueiri TK, Jawde RA, Bruening K, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 2006 Dec;17(12):1766–71.PubMedCrossRefGoogle Scholar
  132. 132.
    Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb;22(2):414–23.PubMedCrossRefGoogle Scholar
  133. 133.
    Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005 Feb;128(3):275–90.PubMedCrossRefGoogle Scholar
  134. 134.
    Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006 Jun 1;107(11):4214–22.PubMedCrossRefGoogle Scholar
  135. 135.
    Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007 Jun;33(4):313–20.PubMedCrossRefGoogle Scholar
  136. 136.
    Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004 Jan 8;350(2):114–24.PubMedCrossRefGoogle Scholar
  137. 137.
    Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 May 15;111(10):4902–7.PubMedCrossRefGoogle Scholar
  138. 138.
    Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006 Nov;91(11):1498–505.PubMedGoogle Scholar
  139. 139.
    Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16;352(24):2487–98.PubMedCrossRefGoogle Scholar
  140. 140.
    Wang M, Weber DM, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol. 2005 Jul;79(3):194–7.PubMedCrossRefGoogle Scholar
  141. 141.
    Sidra G, Williams CD, Russell NH, Zaman S, Myers B, Byrne JL. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica. 2006 Jun;91(6):862–3.PubMedGoogle Scholar
  142. 142.
    Wu P, Davies FE, Horton C, Jenner MW, Krishnan B, Alvares CL, et al. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide – vincristine – doxorubicin – methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma. 2006 Nov;47(11):2335–8.PubMedCrossRefGoogle Scholar
  143. 143.
    Kropff MH, Lang N, Bisping G, Domine N, Innig G, Hentrich M, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol. 2003 Aug;122(4):607–16.PubMedCrossRefGoogle Scholar
  144. 144.
    Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004;5(2):112–7.PubMedCrossRefGoogle Scholar
  145. 145.
    Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, Polo-Zarzuela M, Sureda A, Barrenetxea C, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia. 2004 Apr;18(4):856–63.PubMedCrossRefGoogle Scholar
  146. 146.
    Suvannasankha A, Fausel C, Juliar BE, Yiannoutsos CT, Fisher WB, Ansari RH, et al. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. Oncologist. 2007 Jan;12(1):99–106.PubMedCrossRefGoogle Scholar
  147. 147.
    Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002 Aug 15;100(4):1168–71.PubMedCrossRefGoogle Scholar
  148. 148.
    Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003 Jul 15;21(14):2732–9.PubMedCrossRefGoogle Scholar
  149. 149.
    Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood. 2006 Jul 1;108(1): 403; author reply 4.PubMedCrossRefGoogle Scholar
  150. 150.
    Morgan GJ, Schey SA, Wu P, Srikanth M, Phekoo KJ, Jenner M, et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol. 2007 May;137(3): 268–9.PubMedCrossRefGoogle Scholar
  151. 151.
    Richardson P, Jagannath S, Raje N, Jakubowiak A, Lonial S, Avigan D, et al. Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase 1/2 study. ASH Annual Meeting Abstracts. 2007 November 16, 2007;110(11):187.Google Scholar
  152. 152.
    Richardson PG, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, et al. Lenalidomide Plus Bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. ASH Annual Meeting Abstracts. 2006 November 16, 2006;108(11):405.Google Scholar
  153. 153.
    Richardson P, Jagannath S, Raje N, Jakubowiak A, Lonial S, Ghobrial I, et al. Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): preliminary results of a phase II study. ASH Annual Meeting Abstracts. 2007 November 16, 2007;110(11): 2714.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of Hematology, Department of Internal MedicineCollege of Medicine, Mayo ClinicRochesterUSA
  2. 2.Div of HematologyMayo Clinic College of Med.Rochester

Personalised recommendations